Mauna Kea Technologies (Paris:MKEA) (Euronext: MKEA, FR0010609263), leader in the optical biopsy market, announced today it has installed its flagship Cellvizio system at the Apollo Gleneagles Hospital in Kolkata, a leading center of excellence in Gastroenterology in India, part of the Apollo Hospitals Group.
"This is great news for our patients", said Dr Mahesh Goenka, Chief of Gastroenterology at Apollo Gleneagles, "Optical Biopsy with Cellvizio can now be used to improve patient management in several key gastroenterological indications and I am proud to be the first doctor in India to provide such advanced care. "
Apollo Hospitals has been the forerunner of integrated healthcare in Asia, as well as globally. Apollo Gleneagles Hospitals is a joint venture of Apollo Group of Hospitals, India and Parkway Health of Singapore. The Parkway Group is a leading healthcare group in Asia. A 510-bed multi-specialty tertiary care hospital - Apollo Gleneagles Hospitals Kolkata, is a perfect blend of technological excellence, complete infrastructure, competent care and heartfelt hospitality.
"Once again, Apollo Hospitals is at the forefront of patient care with the most advanced medical technologies available", declared Dr Rupali Basu, CEO at Eastern region and Apollo Gleneagles Hospital. "The addition of Cellvizio to one of our leading centers of excellence in Gastroenterology is a great example of how we continue to break new grounds in India."
Sacha Loiseau, CEO and founder of Mauna Kea Technologies, added: "We continue to make strong progress in our Asia-Pacific development and this first prestigious installation in India is another milestone in this high-growth region. We look forward to working with the Apollo Hospitals Group to improve patient care throughout the subcontinent. "
Study tracks health and quality of life in chronically critically ill COVID-19 patients months after hospital discharge